Can dexrazoxane reduce myocardial injury in anthracycline-treated children with acute lymphoblastic leukemia?
Jeffrey H Silber
Correspondence The Children's Hospital of Philadelphia, Center for Outcomes Research, 3535 Market Street, Suite 1029, Philadelphia, PA 19104, USA
Email silber@email.CHOP.edu
This article has no abstract so we have provided the first paragraph of the full text.
The study by Lipshultz et al. may well mark the beginning of a new era in both the prevention of anthracycline-associated cardiotoxic effects using the free-radical scavenger, dexrazoxane, and in the monitoring of anthracycline-associated cardiac damage using troponin T. The results of this paper should prompt oncologists to consider using dexrazoxane whenever possible, and to question how measurement of troponin T can be optimally incorporated into our monitoring algorithms.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.